Kornimate/medical-research-clean huggingface dataset:
throwing velocity and patient reported outcomes in elite level handball players after completion of shoulder-pacemaker strength training

Conditions: Shoulder Dislocation

Summary: the successful application of treatment protocols using motion-triggered neuromuscular electrical stimulation (nmes) for treatment-resistant functional posterior shoulder instability was recently demonstrated. the purpose of this study is to evaluate the concept of a motion-triggered nmes training protocol through objective clinical outcome parameters and its impact on external rotational (er) shoulder strength and throwing velocity in healthy, elite-level handball players.

the aim of this study is to evaluate the concept of a motion-triggered nmes training protocol through objective clinical outcome parameters and its impact on external rotational (er) shoulder strength and throwing velocity in healthy, elite-level handball players. it is hypothesized that a 6-week motion-triggered nmes shoulder strengthening training protocol in elite-level handball players would lead to an increase in throwing velocity due to an improved motor ability and er shoulder strength.

Eligibility criteria:
inclusion criteria: * elite level handball players healthy and actively competing at the time of the study * patients must be at least 18 years at the time of signing the informed consent * pregnancy must be ruled out in the case of female participants (e.g., pregnancy test) * patient must be available for all specified assessments throughout the study duration * all patients are required to give written informed consent before enrollment exclusion criteria: * age \&lt;18, * history of type i or ii shoulder instability according to the stanmore classification12, * existing pain syndrome (defined by pain at rest or during motion that is not caused by dislocation and impedes training), * recent shoulder surgery (\&lt;1 year). * contraindication to spm treatment (e.g., cardiac pacemaker) * neurological disorders or nerve injuries causing the instability * uncontrolled alcohol or substance abuse

Keywords: motion-triggered neuromuscular electrical stimulation-enhanced strength training
a study to evaluate injection pain and local tolerability following subcutaneous (sc) administration of tv-46046

Conditions: Contraception

Summary: the purpose of this study is to evaluate the local tolerability associated with the sc administration of tv-46046, and inform next steps of the tv-46046 development program.

eligible participants will be enrolled and receive 1 of each of the 4 sc study injections in each abdominal quadrant approximately 1 hour apart: 120 milligrams (mg)/0.3 milliliter (ml) of tv-46046, 60 mg/0.3 ml of 1:1 saline diluted tv-46046, 0.3 ml of tv-46046 placebo and 104 mg/0.65 ml depo-subq 104 per the assigned sequence.

Eligibility criteria:
inclusion criteria: * participant has a low risk of pregnancy (that is, sterilized, in exclusively same-sex partnership, in menopause and/or post-menopausal, abstinent, in a monogamous relationship with vasectomized partner, using nonhormonal intrauterine device \[iud\], or consistent use of condoms) * participant is not pregnant and does not have desire to become pregnant in the subsequent 18 months * participant had a normal mammogram within the last year, if 40 years or older * participant has no skin disorders or skin allergies * additional criteria apply, please contact the investigator for more information exclusion criteria: * participant has hypertension * participant has ischemic heart disease or a history of ischemic heart disease * participant has a history of stroke * participant has a history of thromboembolic event(s) * participant has systemic lupus erythematosus * participant has rheumatoid arthritis and is undergoing immunosuppressive therapy * participant has migraine with aura * participant has unexplained vaginal bleeding * participant has diabetes * participant has a strong family history of breast cancer * participant has cervical cancer or a history of cervical cancer * participant has severe cirrhosis (decompensated) or liver tumors * participant has known significant renal disease * participant has a history of diagnosed clinical depression or bipolar disorder, with or without suicidal ideation, and/or history of suicide attempt * participant is currently using hormonal contraception * participant had an injection of dmpa (depo-provera ci or depo-subq 104) in the past 12 months; or combined injectable in the last 3 months * participant is chronically using pain medication * participant has a plan to move to another location in the next 18 months * additional criteria apply, please contact the investigator for more information
randomized controlled trial of lifestyle intervention postpartum in primary health care

Conditions: Overweight; Obesity

Summary: chronic diseases such as overweight and cardiovascular diseases represent important threats to women's health. pregnancy and lactation are associated with changes in weight, body composition and lipid metabolism and affect the risk of developing these chronic illnesses. our group has conducted a randomized clinical trial (leva) to evaluate overweight/obese women's ability to make longterm lifestyle changes during the postpartum (pp) period, under ideal study conditions. physiological mechanisms for weight reduction were investigated with precise methodology. however, effectiveness studies under different conditions are crucial for the development of effective programs for the primary health care sector. hence, the interest for translational research that brings results from clinical trials to the primary health care sector has increased. the aim of this effectiveness-study is to investigate if dietary restrictions pp lead to significantly greater weight reduction among overweight/obese women, compared to no intervention, in a longterm perspective. in total 106 women will be recruited 10 wk pp and randomized into 1) control group; 2) dietary restrictions in individualized intervention during 12 wks. one and two years pp long term effects are evaluated. positive results may be integrated into usual practice after the study ends.


Eligibility criteria:
inclusion criteria \* bmi at 10 w postpartum \>= 27.0 exclusion criteria \*serious disease in mother or child

Keywords: diet lifestyle
the effect of web-assisted peer education for early diagnosis of breast cancer on health beliefs, knowledge levels and breast self-examination in university students

Conditions: University Students; Breast Self-examination; Health Education

Summary: the aim of this study was to examine the effect of web-supported peer education on health beliefs, knowledge levels and breast self-examination in university students.

in line with the general purpose of the study, an experimental design will be used in the study. the population of this study consists of female students of ankara medipol university. considering that there may be dropouts from the study in line with the determined sample size, 200 students (intervention; n=100, control; n=100) who were excluded from the exclusion criteria and who agreed to participate in the study were planned to constitute the study group. hypotheses of the research between the experimental group and the control group, which received peer education on breast cancer and breast self-examination (bse); h1a1: there is a difference in terms of the sensitivity subscale score average. h1b1: there is a difference in terms of the mean score of the seriousness/importance subscale. h1c1: there is a difference in terms of the average score of the benefit perception subscale. h1d1: there is a difference in terms of the average score of the obstacle perception subscale. h1e1: there is a difference in terms of the mean score of the trust subscale. h1f1: there is a difference in terms of the health motivation subscale score average. h2a1: there is a difference in terms of the average knowledge score. h3a1: there is a difference in terms of performing breast self-examination.

Eligibility criteria:
inclusion criteria: * young women who do not have any diagnosis of cancer or breast cancer * who have no communication barriers * who are not pregnant or breastfeeding * who volunteer to participate in the study exclusion criteria: * participants with a previous cancer diagnosis * chcmm training and who were absent for more than two sessions in the intervention group

Keywords: breast self-examination health education university students breast cancer
helmet ventilation in acute hypercapnic respiratory failure

Conditions: Hypercapnic Respiratory Failure; Chronic Obstructive Pulmonary Disease

Summary: lack of tolerance to the treatment, makes the interface choice for non-invasive ventilation (niv) one of the key factor. to date the helmet is rarely used in acute hypercapnic respiratory failure (ahrf), because of its large dead space, despite in hypoxic respiratory failure, it is largely employed as a "rotating" strategy when the facial mask is poorly tolerated. in a multicenter randomized controlled trial, the investigators will compare the clinical efficacy of a new helmet designed to specifically improve the performance in chronic obstructive pulmonary disease (copd) versus a full face mask during an episode of ahrf.


Eligibility criteria:
inclusion criteria: * ph \ 45 mmhg * respiratory rate \> 20 b/min exclusion criteria: * hypoxic respiratory failure * coma * inability to stand niv * lack of informed consent

Keywords: copd niv acute hypercapnic respiratory failure copd patients with hypercapnic respiratory failure
inhaled allergen challenge methodology: assessment of a vibrating mesh nebulizer for allergen administration

Conditions: Asthma

Summary: this study will assess the aerogen solo® (solo®) vibrating mesh nebulizer as a potential new device for use in allergen challenge testing.

this will be a multi-center, randomized, cross-over study utilizing the expertise of three canadian academic centers (university of saskatchewan, mcmaster university, laval university) that have been performing allergen inhalation challenges and other bronchoprovocation studies for more than forty years. each participant will be required to attend the research lab on five occasions (visits 1-5). at visit 1, study staff will provide an overview of the study purpose and procedure and answer any questions the participant may have. the individual will then provide consent if they wish to participate (i.e. sign the consent form). skin prick testing to determine relevant allergen sensitivities and to determine which allergen extract will be used for the skin test endpoint (ste) and allergen inhalation challenge will then be performed. the participant will be randomized with respect to which nebulizer (solo® or wright) will be used first. the choice of nebulizer for the first participant will be via blinded draw. subsequent nebulizer assignments will alternate. participants will undergo the ste procedure and methacholine challenge testing (mct) at visit 2; an allergen challenge will be done the next day at visit 3 using the same nebulizer as was used for the mct at visit 2. visits 4 and 5 will also be performed on consecutive days and will involve methacholine and allergen challenge testing, respectively, using the nebulizer that was not used at visits 2 and 3. a minimum of two weeks must separate visits 3 and 4.

Eligibility criteria:
inclusion criteria: * baseline fev1 greater than or equal to 70% * positive response to inhaled methacholine (i.e. pd20 less than 400mcg) * evidence of atopy (i.e. positive skin prick test to an allergen that can be used for the inhalation challenge * absence of respiratory infection for at least 4 weeks * absence of allergen exposure (or other trigger of upper or lower respiratory symptoms) for at least 4 weeks * current nonsmoker (ex-smoker allowed; case by case basis; investigator discretion) * require only infrequent short-acting beta2 agonist (i.e. salbutamol or terbutaline) to treat/control asthma (i.e. no inhaled corticosteroid or combination therapies, no intranasal corticosteroid; anti-histamines etc.) * general good health with no other medical condition, medication use or lifestyle activities that would influence the outcome of the allergen challenge exclusion criteria: * pregnant or lactating

Keywords: vibrating mesh nebulizer allergen challenge
post authorization safety study moderna covid-19 primary vaccine

Conditions: COVID-19

Summary: this study is post authorization safety study (pass) phase iv of moderna covid-19 primary vaccine

this study is post authorization safety study (pass) phase iv, to assess any local and systemic reaction after immunization with moderna covid-19 vaccine using retrospective cohort study trial design to assess safety profile following moderna covid-19 primary vaccine in healthy adults aged ≥ 18 years in indonesia.

Eligibility criteria:
inclusion criteria: * clinically healthy adults aged ≥ 18 years. * subjects have been informed properly regarding the study and accepted to be enrolled in this study. exclusion criteria: - subjects concomitantly enrolled or scheduled to be enrolled in another trial at the time of receiving the moderna covid-19 vaccine.

Keywords: covid-19 moderna vaccine safety vaccine
extended niacin/laropiprant in patients with type 2 diabetes (0524a-069)

Conditions: Diabetes Mellitus Type 2

Summary: a study to assess the efficacy and tolerability of er (extended release) niacin/laropiprant versus placebo in type 2 diabetes mellitus patients.


Eligibility criteria:
inclusion criteria: * patients between the ages of 18 to 80 years with type 2 diabetes who are on a stable dose of antidiabetic medication for at least 3 months exclusion criteria: * patients taking cholestin, niacin (\>50 mg/day), fibrate therapy, hormonal contraceptives, intermittent hormone replacement therapy, or certain corticosteroids * patients with any of the following conditions: active liver disease or kidney disease, poorly controlled high blood pressure, active peptic ulcer, or other heart or blood diseases * patients with abnormal laboratory results from a blood test that will be given before starting the study
perioperative effect of atenolol on cytokine profiles

Conditions: Surgery

Summary: studies have shown that beta-blockers such as atenolol when given in the perioperative period reduce morbidity and mortality. one study showed that atenolol given just during the surgery period, seemed to improve outcomes up to 2 years later. this is hard to explain since beta-blockers act on the body by blocking the effects of adrenalin and thereby lowering heart rate and blood pressure. this study is designed to find out if perioperative atenolol might exert its long term effects through an anti-inflammatory mechanism rather than by lowering heart rate and blood pressure. it is known that inflammation increases after surgery as part of the healing process. however, it is also becoming clear that low-grade chronic inflammation can also lead to long term adverse effects.


Eligibility criteria:
inclusion criteria: * elective abdominal, orthopedic, or gynecologic surgery * ability to give informed consent * ability to tolerate beta-blocker therapy * ability to comply with follow-up requirements exclusion criteria: * currently receiving beta-blocker therapy * ekg documented 2nd or 3rd degree heart block * ekg documented sinus bradycardia * serum creatinine \> 2.0 * current treatment asthma * history of rheumatoid arthritis * history of crohn's disease * history of lupus * history of inflammatory cancer

Keywords: perioperative beta-blockers inflammation outcomes
sorafenib and tace as adjuvant therapy for mvi in hcc patients after radical resection

Conditions: Hepatocellular Carcinoma

Summary: this study is a prospective non-randomized controlled study. the purpose of this study is to evaluate the validity and safety of sorafenib and transcatheter arterial chemoembolization (tace) for microvascular invasion (mvi) in hepatocellular carcinoma (hcc) patients after radical surgery.

hcc is the sixth most common malignancy worldwide.selected patients with hcc are candidates for potentially curative therapy, such as hepatic resection and liver transplantation. nevertheless,tumor recurrence is 70 % at 5 years after resection and 15-30 % after liver transplantation,leading to tumor-related death.mvi is currently one of the most critical factors predictive of hcc recurrence.there are no approved effective interventional measures to improve the outcome of this patients with mvi.the purpose of this study is to explore the validity and safety of sorafenib and tace for mvi in hcc patients after radical resection.the candidates will be assigned to sorafenib group (about 30 cases),tace group (about 30 patients) and control group (about 30 cases)，according to the willingness of the subject.all patients will be followed up for 3 years and recurrence-free survival and overall survival will be recorded.

Eligibility criteria:
inclusion criteria: * 18-75 years of age; * the liver tumor has been radically resected; * postoperative pathology proved to be hepatocellular carcinoma with negative margin and microvascular invasion; * imaging evaluations(ct/mri) were performed at 1 month after the resection and no area of enhancement was seen; * child-pugh a; * eastern cooperative oncology group(ecog) body condition score (ps) 0-1; * then patients understand and voluntarily signed a written informed consent; exclusion criteria: * recurrent hcc; * pathology-proved multifocal hcc or hcc with satellite nodules; * tumor thrombus in portal vein or inferior vena cava trunk; * patients with extrahepatic metastasis found by radiologic or pathologic examination; * severe dysfunction of the heart, kidney, or other organs.the patients cannot tolerate tace or sorafenib after general assessment of the situation; * enrolled in other clinical study at the same time; * previously treated with other antitumor treatments except the resection; * the researchers believe that the patient does not fit this study; * pregnant or lactating women.

Keywords: sorafenib transcatheter arterial chemoembolization hepatocellular carcinoma microvascular invasion
study of natural killer cells in bone marrow and blood samples from patients with and without hematologic cancer

Conditions: Leukemia; Multiple Myeloma and Plasma Cell Neoplasm

Summary: rationale: collecting and storing samples of bone marrow and blood from patients with cancer to study in the laboratory may help doctors find better ways to treat the cancer. purpose: this research study is looking at natural killer cells in bone marrow and blood samples from patients with hematologic cancer and from patients who do not have cancer.

objectives: * to collect normal and malignant cells in bone marrow and peripheral blood samples from patients with acute myeloid leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, or multiple myeloma and from patients with no malignancy to use as target cells in cytotoxicity assays. * to collect information about hla type and immunophenotype of malignant cells as determined by clinical flow cytometry. outline: bone marrow aspirates and/or peripheral blood samples are collected and used as target cells in standard cytotoxicity assays, with notch-induced natural killer (n-nk) cells as the effector cells, to determine whether n-nk cells are capable of killing malignant cells and/or non-malignant cells. receptor-blocking antibodies may be added to determine which nk cell receptors are responsible for malignant cell recognition and killing. information about hla type and immunophenotype of the malignant cells is collected from the patient's medical record.

Eligibility criteria:
disease characteristics: * meets one of the following criteria: * no evidence of malignancy * diagnosis of one of the following: * acute myeloid leukemia * acute lymphoblastic leukemia * chronic myelogenous leukemia * multiple myeloma patient characteristics: * not specified prior concurrent therapy: * not specified

Keywords: childhood chronic myelogenous leukemia chronic myelogenous leukemia adult acute lymphoblastic leukemia childhood acute lymphoblastic leukemia adult acute myeloid leukemia childhood acute myeloid leukemia/other myeloid malignancies multiple myeloma
localization of breast cancer with the sirius pintuition magnetic seed

Conditions: Breast Cancer Surgery

Summary: a prospective pilot study in the czech republic examining the use of magnetic seed sirius pintuition for the localization of non-palpable malignant breast tumors and pathological lymph nodes.


Eligibility criteria:
inclusion criteria: * breast cancer confirmed by a core-cut biopsy * localisation of non-palpable breast cancer or pathological lymph node with a magnetic seed sirius pintuition * breast cancer surgery in surgical dpt, silesian hospital in opava exclusion criteria: * disagree with participation in the study
18f-mfbg lafov pet/ct compared to 123i-mibg scintigraphy spect/ct for evaluation of children with neuroblastoma

Conditions: Neuroblastoma

Summary: this is a study evaluating the positron-emitting radiopharmaceutical 18f-mfbg compared to 123i-mibg scintigraphy for imaging of neuroblastoma

this is a prospective study designed to assess the use of 18f-mfbg pet imaging compared to 123i-mibg scintigraphy in subjects with known or presumed neuroblastoma. eligible participants will have either histopathologically established diagnosis of neuroblastoma or a presumed diagnosis based on signs, symptoms, physical examination, imaging findings, and laboratory and genetic test results. subjects will only be administered 18f-mfbg if they have undergone or are scheduled to undergo a 123i-mibg within +/- 7 days of the date of the 18f-mfbg scan. subjects should not have received any chemotherapy, immunotherapy or radiotherapy between the clinical and 18f-mfbg imaging studies. 18f-mfbg pet studies will be evaluated by 2 independent teams of blinded readers: a nuclear medicine physician and a radiologist, both specialized in pediatric nuclear medicine co-reading side-by side. the clinical 123i-mibg is also evaluated by 2 independent teams of blinded readers: a nuclear medicine physician and a radiologist, both specialized in pediatric nuclear medicine co-reading side-by side. blinded readers will record whether findings on 18f-mfbg and 123i-mibg scans are consistent with neuroblastoma. subject-level diagnostic performance will be assessed on the basis of differencies in lesion-counting between the blinded 18f-mfbg scan interpretation and the 123i-mibg scan. in case of discrepancy, independently assessed by an expert panel.

Eligibility criteria:
inclusion criteria: 1. an established diagnosis of neuroblastoma based on unequivocal histopathology from tissue obtained at any time prior to enrolment in the trial; or b) a presumed diagnosis of neuroblastoma based on signs, symptoms, physical examination, imaging findings, and laboratory and genetic test results, including individuals in whom therapy has already been empirically initiated. 2. the subject has undergone or is scheduled to undergo evaluation of neuroblastoma disease status, including 123i-mibg +/- 7 days to the date of 18f-mfbg imaging, with no therapy between such evaluation. 3. ability of subject or subject's legal guardian to understand and sign a written informed consent document. - exclusion criteria: 1. pregnancy -

Keywords: 18f-mfbg meta-fluorobenzylguanidine large axial field of view pet/ct, lafov pet/ct total body pet/ct